IMIDomics

company

About

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs).

  • 11 - 50

Details

Last Funding Type
Corporate Round
Industries
Biotechnology,Health Care
Founded date
Jan 1, 2015
Number Of Employee
11 - 50
Operating Status
Active

IMIDomics is a unique company tackling Immune-Mediated Inflammatory Diseases (IMIDs). As an innovative leader in discovery and application of biomarkers and new targets to monitor and cure IMIDs, we create value through the combination of the world's largest IMID biobank, extensive relevant clinical expertise, high-throughput genomic and genetic analysis, and intellectual property. IMIDomics is located at Vall d'Hebron Hospital in Barcelona, Spain and on the HudsonAlpha Institute campus in Huntsville, Alabama.

Funding Rounds

Number of Funding Rounds
Total Funding Amount
1
IMIDomics has raised a total of — in funding over 2 rounds. Their latest funding was raised on Feb 15, 2022 from a Corporate Round round.
Announced Date Round Money Raised Number of Investors Lead Investors Post Valuation
Feb 15, 2022 Corporate Round 1 Evotec Detail

Investors

Number of Lead Investors
Number of Investors
1
1
IMIDomics is funded by 1 investors. Evotec are the most recent investors.
Investor Name Lead Investor Funding Round
Evotec Yes Corporate Round